EUCTR2007-003012-61-BE进行中（未招募）不适用
A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)
sanofi recherche & developpement0 个研究点目标入组 720 人开始时间: 2007年9月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 720
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who are at least 18 years of age and with a diagnosis of NASH by liver biopsy performed within last 6 months (based on pre-defined histological criteria as confirmed by a central pathologist)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria related to study methodo
- •1. Refusal or inability to give informed consent to participate in the study
- •2. Average alcohol ingestion >21 units/wk (males) or >14 units/wk (females) [self-administered quantity-frequency and 7-day recall tests and confirmed by a family member]
- •3. No history of or presence of overt diabetes (i.e., FPG<126 ng/mL / 7.0 mmol/L)
- •4. Other cause of chronic liver disease and/or hepatic steatosis: (see protocol)
- •5. Any contraindication to liver biopsy based on local standard for pre-liver biopsy risk
- •assessment (for examples: see protocol)
- •6. History of or planned gastrointestinal bypass surgery/intervention (i.e., bariatric surgery)
- •7. Hepatic Cirrhosis with a Child-Pugh classification of B or C (score >6)
- •8. Concomitant Hepatocellular Carcinoma (HCC) (i.e., AFP >100 ng/mL on screening Liver Disease Panel or otherwise unexplained liver mass visualized on ultrasound or computed tomography examination of the liver)
- •9. Previous hepatic transplantation
- •10. Recent significant weight loss (>5% TBW within previous 6 months)
- •11. ALT or AST >10 x ULN at screening or within 3 months of screening
- •12. Recent (within 6 months of baseline liver biopsy and screening visit) or concomitant use of agent known to cause hepatic steatosis: corticosteroids, amiodarone, methotrexate, tamoxifen, tetracycline, high dose estrogens (standard HRT and oral contraceptive doses allowed), valproic acid
- •13. Use of insulin, biguanide, sufonylurea or thiazolidinedione within last 6 months before baseline liver biopsy and screening visit
- •14. Recent (within 3 months of baseline liver biopsy and screening visit) change in dose/ regimen or introduction of: Vitamin E, Vitamin C, betaine, s-adenosyl methionine (SAM), ursodeoxycholate (UDCA), silymarin (silybin), fibrate, statin, pentoxyfilline, angiotensin II inhibitor
- •15. Recent (within 3 months of baseline liver biopsy and screening visit) change in dose/ regimen or introduction of weight loss agent such as: orlistat, sibutramine, rimonabant
- •16. Any situation that in the Investigator’s opinion, may interfere with optimal study participation such as alcohol or drug abuse, domicile too distant from study site, potential non-compliance during the study or inability to cooperate because of a language problem or poor mental development
- •17. Participation in any clinical study of an investigational agent within 30 days or five half-lives of the investigational agent, whichever is longer
- •18. Presence of clinically relevant cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or any acute infectious disease or signs of acute illness that, in the opinion of the Investigator might compromise the patient’s safe participation in this trial, including uncontrolled serious psychiatric illness such as major depression within the last 2 years, suicidal ideation of Type 4(1) or Type 5(2) on the C-SSRS or suicidal behavior within the last month, medical history of suicide attempt and history of other severe psychiatric disorder (eg, schizophrenia or bipolar disorder). Any patient who scores 15 or higher on the PHQ-9 administered at the screening or randomization visit, or any patient whose response on the C-SSRS at the screening or randomization visit indicates suicidal behavior is concerning for suicidal ideation (active suicidal ideation with some intent to act, without specific plan and active s
研究者
相似试验
尚未招募
3 期
Cannabinoid in cancer pain management.CTRI/2023/06/054536Pillcraft Private Limited
进行中（未招募）
不适用
A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH)EUCTR2007-003013-14-BEsanofi-aventis recherche & development720
进行中（未招募）
不适用
A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)</ - STRONGon diabetic patients with Non-Alcoholic Steato-Hepatitis (NASH)MedDRA version: 9.1Level: LLTClassification code 10053219Term: Non-alcoholic steatohepatitisEUCTR2007-003012-61-ITsanofi-aventis recherche & development720
进行中（未招募）
不适用
A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)EUCTR2007-003012-61-FRsanofi-aventis Recherche & D2veloppement720
招募中
不适用
Clinical study to evaluate the efficacy of HUDC_VT in patients with bacterial vaginosisCertain infectious and parasitic diseasesKCT0002268Koera University Guro Hospital150